Literature DB >> 23137508

Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.

Kalkidan Bishu1, Anita Deswal, Horng H Chen, Martin M LeWinter, Gregory D Lewis, Marc J Semigran, Barry A Borlaug, Steven McNulty, Adrian F Hernandez, Eugene Braunwald, Margaret M Redfield.   

Abstract

BACKGROUND: Acute decompensated heart failure (ADHF) occurs with preserved (heart failure with preserved ejection fraction [HFpEF] ≥50%) or reduced (heart failure with reduced ejection fraction [HFrEF] <50%) ejection fraction. Natriuretic peptide (NP) levels are lower in HFpEF than HFrEF. We hypothesized that lower NP levels in HFpEF may be associated with other differences in biomarkers, specifically, renin-angiotensin-aldosterone system (RAAS) activation, oxidative stress, and a biomarker that reflects collagen synthesis.
METHODS: In this prespecified ancillary analysis of patients with ADHF enrolled in the Diuretic Optimization Strategies Evaluation study, clinical features and N-terminal pro-B-type NP, cystatin C, plasma renin activity, aldosterone, oxidative stress (uric acid), and procollagen type III N-terminal peptide were compared in HFpEF and HFrEF at enrollment and 60-day follow-up.
RESULTS: Compared with HFrEF (n = 219), HFpEF (n = 81) patients were older, heavier, more commonly female, less treated with RAAS antagonists, but with similar New York Heart Association class, jugular venous pressure, and edema severity. N-terminal pro-B-type NP was lower, and systolic blood pressure and cystatin C were higher in HFpEF. Despite higher systolic blood pressure and less RAAS antagonist use in HFpEF, plasma renin activity and aldosterone levels were similar in HFpEF and HFrEF as were uric acid and procollagen type III N-terminal peptide levels. Changes in biomarker levels from enrollment to 60 days were similar between HFrEF (n = 149) and HFpEF (n = 50).
CONCLUSION: Lower NP levels in decompensated HFpEF occur in association with similar ADHF severity, more impaired vascular and renal function but similar elevation of biomarkers that reflect RAAS activation, oxidative stress, and collagen synthesis as in HFrEF.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23137508      PMCID: PMC3875288          DOI: 10.1016/j.ahj.2012.08.014

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  36 in total

1.  Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure.

Authors:  Dalane W Kitzman; William C Little; Peter H Brubaker; Roger T Anderson; W Gregory Hundley; Christian T Marburger; Bridget Brosnihan; Timothy M Morgan; Kathryn P Stewart
Journal:  JAMA       Date:  2002-11-06       Impact factor: 56.272

2.  Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance.

Authors:  H Finney; D J Newman; C P Price
Journal:  Ann Clin Biochem       Date:  2000-01       Impact factor: 2.057

3.  Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study.

Authors:  Alan S Maisel; James McCord; Richard M Nowak; Judd E Hollander; Alan H B Wu; Philippe Duc; Torbjørn Omland; Alan B Storrow; Padma Krishnaswamy; William T Abraham; Paul Clopton; Gabriel Steg; Marie Claude Aumont; Arne Westheim; Cathrine Wold Knudsen; Alberto Perez; Richard Kamin; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough
Journal:  J Am Coll Cardiol       Date:  2003-06-04       Impact factor: 24.094

Review 4.  Cystatin C: an improved estimator of glomerular filtration rate?

Authors:  Omar F Laterza; Christopher P Price; Mitchell G Scott
Journal:  Clin Chem       Date:  2002-05       Impact factor: 8.327

5.  Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis.

Authors:  Vikas R Dharnidharka; Charles Kwon; Gary Stevens
Journal:  Am J Kidney Dis       Date:  2002-08       Impact factor: 8.860

6.  Impact of obesity on plasma natriuretic peptide levels.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

Review 7.  Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis.

Authors:  Karen Hogg; Karl Swedberg; John McMurray
Journal:  J Am Coll Cardiol       Date:  2004-02-04       Impact factor: 24.094

8.  Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators.

Authors:  C R Benedict; D H Weiner; D E Johnstone; M G Bourassa; J K Ghali; J Nicklas; P Kirlin; B Greenberg; M A Quinones; S Yusuf
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

9.  Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath.

Authors:  Alan Maisel; Judd E Hollander; David Guss; Peter McCullough; Richard Nowak; Gary Green; Mitchell Saltzberg; Stefanie R Ellison; Meenakshi Awasthi Bhalla; Vikas Bhalla; Paul Clopton; Robert Jesse
Journal:  J Am Coll Cardiol       Date:  2004-09-15       Impact factor: 24.094

10.  A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction.

Authors:  T L Stevens; J C Burnett; M Kinoshita; Y Matsuda; M M Redfield
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more
  33 in total

1.  Right ventricular function in heart failure with preserved ejection fraction: a community-based study.

Authors:  Selma F Mohammed; Imad Hussain; Omar F AbouEzzeddine; Omar F Abou Ezzeddine; Hiroyuki Takahama; Susan H Kwon; Paul Forfia; Véronique L Roger; Margaret M Redfield
Journal:  Circulation       Date:  2014-11-12       Impact factor: 29.690

Review 2.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.

Authors:  Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

3.  Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.

Authors:  Ryunosuke Okuyama; Junnichi Ishii; Hiroshi Takahashi; Hideki Kawai; Takashi Muramatsu; Masahide Harada; Akira Yamada; Sadako Motoyama; Shigeru Matsui; Hiroyuki Naruse; Masayoshi Sarai; Midori Hasegawa; Eiichi Watanabe; Atsushi Suzuki; Mutsuharu Hayashi; Hideo Izawa; Yukio Yuzawa; Yukio Ozaki
Journal:  Heart Vessels       Date:  2017-02-02       Impact factor: 2.037

Review 4.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 5.  Circulating biomarkers in patients with heart failure and preserved ejection fraction.

Authors:  Eileen O'Meara; Simon de Denus; Jean-Lucien Rouleau; Akshay Desai
Journal:  Curr Heart Fail Rep       Date:  2013-12

6.  BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study.

Authors:  Umair Khalid; Lisa Miller Wruck; Pedro Miguel Quibrera; Biykem Bozkurt; Vijay Nambi; Salim S Virani; Hani Jneid; Sunil Agarwal; Patricia P Chang; Laura Loehr; Sukhdeep Singh Basra; Wayne Rosamond; Christie M Ballantyne; Anita Deswal
Journal:  Int J Cardiol       Date:  2017-01-31       Impact factor: 4.164

Review 7.  Heart Failure With Preserved Ejection Fraction: A Perioperative Review.

Authors:  Sasha K Shillcutt; M Megan Chacon; Tara R Brakke; Ellen K Roberts; Thomas E Schulte; Nicholas Markin
Journal:  J Cardiothorac Vasc Anesth       Date:  2017-08-30       Impact factor: 2.628

8.  Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.

Authors:  Brian Bostick; Javad Habibi; Lixin Ma; Annayya Aroor; Nathan Rehmer; Melvin R Hayden; James R Sowers
Journal:  Metabolism       Date:  2014-04-12       Impact factor: 8.694

9.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

Review 10.  Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy.

Authors:  Kalkidan Bishu; Margaret M Redfield
Journal:  Curr Heart Fail Rep       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.